Trending:
Comment
-
11 December 2018
The clinical trial landscape for GSK’s latest acquisition Tesaro
On 3 December 2018, GlaxoSmithKline (GSK) announced that it will be acquiring Tesaro to bolster its drug development portfolio, especially in oncology. With the help of GlobalData’s Pharma Intelligence Center...
-
11 December 2018
Future NASH reimbursement issues may echo HCV therapies
Nonalcoholic steatohepatitis (NASH) therapies with prospective launches post-2020 will likely have reimbursement challenges mirroring those faced by hepatitis C (HCV) therapies approved five years ago, experts said.
-
11 December 2018
Next chapter of Ebola preparation begins as Merck’s V920 nears approval
The Ebola outbreak that began in August in the Democratic Republic of Congo (DRC) has now reached over 400 cases, becoming the second largest outbreak in history according to the...
-
10 December 2018
Allergan’s Phase III Botox trial for depression pushed to H2 2019
Allergan’s Botox (onabotulinumtoxin A) Phase III trial in major depressive disorder (MDD) is slated to initiate in the second half of 2019 (2H19), said a company spokesperson.
-
10 December 2018
Foamix’s rosacea drug FMX103 splits views on sunburn risk
Foamix Pharmaceuticals’ FMX103 (1.5% topical minocycline foam) has experts split over the drug’s real-world ability to protect against sunburn, despite expected FDA approval for moderate-to-severe facial papulopustular rosacea.
-
7 December 2018
ASH 2018: Celgene’s Revlimid looks set for new approvals in NHL
Data from the Phase III AUGMENT trial assessing Revlimid plus rituximab in relapsed/refractory (R/R) indolent lymphoma was presented during the second day of the 2018 American Society of Hematology (ASH)...
-
5 December 2018
Can Bayer’s Jivi match up to the competition in haemophilia A market?
Jivi received EU approval based on results of the Phase II/III PROTECT VIII trial, in which prophylactic dosing, on-demand treatment, and perioperative management were assessed in patients.
-
5 December 2018
Breast cancer clinical trials: top drugs under investigation
Breast cancer is the most commonly diagnosed cancer in women and the second most commonly diagnosed cancer overall.
-
5 December 2018
Enrollment issues are the top factor in clinical trial terminations
GlobalData analysed all terminated trials within the Clinical Trials Database to determine the major reasons for terminations.
-
4 December 2018
Label expansion is a common strategy in Non-Hodgkin’s Lymphoma
An overarching strategy in Non-Hodgkin’s Lymphoma (NHL) research and development, both in the past and current landscape, has been for companies to explore commercialisation across multiple NHL subtypes and lines...